



Patient **access to biosimilar anti-TNF** has expanded by **+15%** in Denmark (2020)



+25,000 more UK patients with mild Rheumatoid arthritis get **access to biologic therapy** thanks to biosimilar competition



Since biosimilar medicines have been available, healthcare systems were able to reinvest **€18BN total savings** across Europe (2021)




A growing opportunity for patients with over **100 new biologic medicines** opening to biosimilar competition by 2030




A considerable opportunity for European healthcare budget: a **\$40BN** market will **open to competition** between 2024-2029



Biosimilars available for cancer treatment have the potential to **reduce treatment costs by €2.4BN** each year in Europe



Biosimilar medicines opportunity remains largely untapped with only **14% volume share** of the accessible market in Europe



Europe remains the global leader with over **50%** of the **biosimilar utilisation**

Patient **access to biosimilar anti-TNF** has expanded by **+15%** in Denmark (2020)



Source: IQVIA Spotlight on Biosimilars in Europe 2021

+25,000 more UK patients
with mild Rheumatoid arthritis get
access to biologic therapy
thanks to biosimilar competition



Source: NICE UK 2021

A growing opportunity for patients with over **100 new biologic medicines** opening to biosimilar competition by 2030




Source: IQVIA Biosimilars Competition in Europe 2020

A considerable opportunity for
European healthcare budget:
a **\$40BN** market will
open to competition between
2024-2029




Source: IQVIA Biosimilars Competition in Europe 2020

Biosimilars available for cancer treatment have the potential to **reduce treatment costs by €2.4BN** each year in Europe




Source: filling the gap https://www.oecd-ilibrary.org/social-issues-migration-health/challenges-in-access-to-oncology-medicines_4b2e9cb9-en

Biosimilar medicines opportunity remains largely untapped with only **14% volume share** of the accessible market in Europe



Source: IQVIA MIDAS® Q4 2020, IQVIA ForecastLink data for post-2020 period, Rx biologics in 23 European markets

Europe remains the global leader
with over **50%** of the
biosimilar utilisation



Source: IQVIA MIDAS MAT Q1 2021; Rx-only. Figures are in Thousands of USD at Constant Exchange Rate

Since biosimilar medicines have been available, healthcare systems were able to reinvest **€18BN** **total savings** across Europe (2021)

